An at-home cancer pill for dogs cleared the FDA — and validated AI drug repurposing

Canine lymphoma has long meant a clinic, an IV, and a chemo protocol most owners can barely afford. A pill that treats it at home changes the economics of that diagnosis, and it now carries the FDA's full approval. The bigger signal for operators sits underneath the drug: the way it was discovered.

Anivive wins full FDA approval for Laverdia, an oral canine lymphoma drug

Anivive Lifesciences said the FDA's Center for Veterinary Medicine granted full approval to Laverdia, verdinexor tablets, for canine lymphoma. It is the first FDA-approved oral, at-home treatment for lymphoma in dogs.

The drug is an XPO1 inhibitor. It works by selectively blocking nuclear-export proteins that cancer cells rely on to survive, a mechanism carried over from human oncology.

The regulatory path is its own story. The FDA first granted Laverdia conditional approval in January 2021 under the Minor Use/Minor Species pathway. After four annual renewals, the sponsor generated the effectiveness data needed to convert that conditional clearance into full approval.

Anivive credits its AI drug-repurposing platform, AniviveSELECT, with identifying and prioritizing verdinexor by connecting human-medicine evidence to veterinary disease biology.

Why the discovery method matters more than the molecule

The approval is meaningful for vets and owners. The repurposing engine behind it is what should interest operators and investors.

AI-guided repurposing just produced a full FDA approval, not a slide

Plenty of companies claim AI will compress drug discovery. Anivive has an actual full-approval label tied to a molecule its platform surfaced from human oncology. That is a rare, concrete proof point in a field heavy on promises.

The economics of repurposing fit veterinary medicine unusually well

Animal-health drug development cannot support human-pharma budgets. Taking a known human compound and validating it for a companion-animal indication sidesteps much of the discovery cost and de-risks the biology. Expect more shots on this goal.

At-home oral dosing reshapes the treatment funnel

An at-home pill widens the population that gets treated at all, because it removes repeated clinic visits and lowers the practical and financial barrier to starting therapy. That expands the addressable market for canine oncology and pulls in owners who would otherwise decline treatment.

There is a discipline point worth keeping. Full approval means the FDA accepted the effectiveness data, but a five-year path from conditional to full approval is also a reminder that 'AI-discovered' does not mean fast. The molecule still spent years generating field data.

Pricing and adoption will decide the commercial outcome. An oral oncology drug only expands access if it is priced for owners who were previously priced out, and only changes practice if vets fold it into their protocols.

What Laverdia's launch will signal about AI-repurposed vet drugs

Watch how Anivive prices and distributes Laverdia, and whether oncology-focused vets adopt it as a first-line at-home option or reserve it as a fallback. That uptake curve is the real test of whether at-home canine oncology becomes a category.

The wider signal to track is the pipeline behind the platform. If AniviveSELECT can surface a second and third repurposed candidate that reaches approval, the story stops being one drug and becomes a repeatable model for building animal-health therapeutics on the back of human pharma's research.

For now, a dog with lymphoma has an at-home option that did not exist before, and the method that found it just earned a credential the whole sector will cite.

Source: Anivive Laverdia FDA approval via PR Newswire. Approval detail via FDA CVM